---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-21-000113"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:45:31.932734+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exagen Q3 2021 revenue $12.3M (+14% YoY); net loss widens to $7.2M; reaffirms FY guidance

## Summary
- Total revenue $12.3M, up 14% YoY; AVISE CTD revenue $9.9M (+34% YoY) on 31,742 tests (+21%).
- Net loss of $7.2M vs. $4.3M a year ago; operating expenses rose to $18.8M from $14.6M.
- Record 1,969 ordering HCPs and 714 adopters; sequential quarterly retention ~99%.
- Signed agreement with Inland Empire Health Plan; in-network lives now ~68.9M.
- Entered pilot to supply AVISE MTX to retail pharmacy chain & major payor partnership.

## SEC filing metadata
- accession: 0001274737-21-000113
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473721000113/0001274737-21-000113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473721000113/exdx-20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-21-000113
- JSON: https://secwatch.observer/filing/0001274737-21-000113.json
- Plain text: https://secwatch.observer/filing/0001274737-21-000113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.